首页 | 本学科首页   官方微博 | 高级检索  
     

CYP2C19药物基因多态性对冠心病患者抗血小板药物个体化治疗的指导
引用本文:黄群,刘奇良,徐敏敏. CYP2C19药物基因多态性对冠心病患者抗血小板药物个体化治疗的指导[J]. 血栓与止血学, 2017, 0(6): 918-920
作者姓名:黄群  刘奇良  徐敏敏
作者单位:同济大学医学院,上海市普陀区人民医院心内科,200127
摘    要:目的检测CYP2C19药物基因多态性对冠心病患者(CHD)抗血小板药物个体化治疗的指导作用。方法2016年1月至2016年12月上海同济大学附属第十人民医院心内科CHD接受PCI治疗的患者200例。这200患者分为在CYP2C19基因多态性检测指导下治疗的A组与采用常规治疗的B组,每组各100人。随后分析A、B两组冠心病患者术后1个月、6个月后发生血栓的情况。结果术后1个月,A组发生血栓的概率显著低于B组(0.2%比1.1%,P=0.036),术后6个月时,A、B两组发生血栓的概率没有统计学意义(0.6%比1.1%,P=0.223),但A组仍保持较低趋势。结论经过PCI治疗的CHD患者在CYP2C19基因多态性检测指导下,氯吡格雷低代谢患者可以得到有效的替换治疗,进而降低术后1个月的血栓发生率,但是对于长远的预后的指导价值需要进一步研究。

关 键 词:CYP2C19  冠心病  氯吡格雷  血栓

CYP2 C19 Gene Polymorphism in Patients with Coronary Heart Disease in the Treatment of Antiplatelet Drugs
HUANG Qun,LIU Qi-liang,XU Min-min. CYP2 C19 Gene Polymorphism in Patients with Coronary Heart Disease in the Treatment of Antiplatelet Drugs[J]. Chinese Journal of Thrombosis and Hemostasis, 2017, 0(6): 918-920
Authors:HUANG Qun  LIU Qi-liang  XU Min-min
Abstract:Objective To evaluate the CYP2C19 gene polymorphisms screening guided antiplatelet therapy after percutaneous coronary intervention ( PCI ) in patients with coronary heart disease ( CHD ) . Methods From Jan 2016 to Dec 2016,a total of 200 CHD patients who were treated by PCI were from The 10 th People ' s Hospital, Tongji University, Shanghai and were sequentially randomized into 2 different groups:CYP2C19 gene polymorphisms screening group ( n =100, group A ) and without CYP2C19 gene polymorphisms screening group ( n =100, group B ).Group A was given Ticagrelo instead of Clopidogrel therapy in patients with low concentration of active metabolite of Clopidogrel during 6 months clinical follow up.The rate of thrombus patients were analyzed at 1 month and 6 months after therapy by corresponding measures .Results At 1 month follow up ,acute myocardial infarction and death rate in group B were greater than in group A (1.1% VS 0.2%,P=0.036).At 6 months follow-up,the difference of thethrombus rate between the 2 groups was no significant (group A 0.6% VS group B 1.1%,P=0.223).Conclusion For patients treated by anti-platelet therapy , the CYP2 C19 gene polymorphisms screening is contribute to the replace therapyof those patients .What's more,it can also drop the occurring rate of patients ' thrombus after 1 month ,who was treated by operation .But the impact on the further therapy needs more observation .
Keywords:CYP2 C19  Coronary heart disease  Clopidogrel  Thrombus
本文献已被 CNKI 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号